Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Evolus

< Previous 1 2 3 4 Next >
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Tickers EOLS
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
From Evolus
Via Business Wire
Tickers EOLS
Evolus Announces Results from European Head-to-Head Filler Trial
From Evolus
Via Business Wire
Tickers EOLS
Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences
From Evolus
Via Business Wire
Tickers EOLS
Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024
From Evolus
Via Business Wire
Tickers EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Tickers EOLS
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance
From Evolus
Via Business Wire
Tickers EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Tickers EOLS
Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications
From Evolus
Via Business Wire
Tickers EOLS
Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe
From Evolus
Via Business Wire
Tickers EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Tickers EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Tickers EOLS
Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau®
From Evolus
Via Business Wire
Tickers EOLS
“Extra-Strength” 40U Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting
From Evolus
Via Business Wire
Tickers EOLS
Evolus to Participate in November Investor Conferences
From Evolus
Via Business Wire
Tickers EOLS
Evolus to Report Third Quarter 2023 Results
From Evolus
Via Business Wire
Tickers EOLS
Final Phase 2 Data Evaluating 40U Dose of PrabotulinumtoxinA-xvfs to be Presented at 2023 ASDS Annual Meeting
From Evolus
Via Business Wire
Tickers EOLS
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
Tickers EOLS
Evolus to Participate in September Conferences
From Evolus
Via Business Wire
Tickers EOLS
Evolus Announces Inducement Grants for New Chief Marketing Officer
From Evolus
Via Business Wire
Tickers EOLS
Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer
From Evolus
Via Business Wire
Tickers EOLS
Evolus Unveils New Branding for Flagship Product Jeuveau® to Reflect Growing and Evolving Consumers
From Evolus
Via Business Wire
Tickers EOLS
Evolus Reports Second Quarter 2023 Results and Provides Business Update
From Evolus
Via Business Wire
Tickers EOLS
Evolus Raises Full-Year Revenue Guidance on Record Second Quarter 2023 Revenue
From Evolus
Via Business Wire
Tickers EOLS
Evolus to Report Second Quarter 2023 Results and Provide Business Update
From Evolus
Via Business Wire
Tickers EOLS
Evolus Launches Nuceiva® (botulinum toxin type A) in Italy
From Evolus
Via Business Wire
Tickers EOLS
Evolus Announces Successful Completion of Phase 2 Study Evaluating “Extra-Strength” Dose of Jeuveau ®
From Evolus
Via Business Wire
Tickers EOLS
Evolus Reaches 1 Million Redemptions in its Evolus Rewards™ Patient Loyalty Program
From Evolus
Via Business Wire
Tickers EOLS
Evolus Reports First Quarter 2023 Results and Provides Business Update
From Evolus
Via Business Wire
Tickers EOLS
Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
From Evolus
Via Business Wire
Tickers EOLS
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.